

Please type a plus sign (+) inside this box

+

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	
Sheet	2	of	3	HEREWITH	Chari
				1642	RAWLZMB
				104322.198	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SR	B	ImmunoGen, Inc. Press Release (February 25, 1999).	✓
SR	C	Apelgren et al, Cancer Research, 50:3540-3544 (1990).	✓
SR	D	Bai et al, Cancer Research, 56:4398-4406 (1996).	✓
SR	E	Dieras et al, 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, page 100, Abstract Nos. 382 and 383 (June 1998).	✓
SR	F	Glisson et al, Journal of Clinical Oncology, 17(8):2309-2315 (August 1999).	✓
SR	G	Griffin et al, The Journal of Immunology, 130(6):2947-2951 (1983).	✓
SR	H	Kibbelaar et al, Journal of Pathology, 159:23-28 (1989).	✓
SR	I	Laguzza et al, J. Med. Chem., 32:548-555 (1989).	✓
SR	J	Liu et al, Proceedings of the American Association for Cancer Research, 38:29 Abstract No. 190 (1997).	✓
SR	K	Liu et al, Proc. Natl. Acad. Sci. USA, 93:8618-8623 (1996).	✓
SR	L	Morris et al, Journal of Clinical Oncology, 16(3):1094-1098 (March 1998).	✓

Examiner Signature		Date Considered	5/5/02
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

+

PTO/SB/08B (10-96)

Applicable for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	
			Filing Date	HEREWITH
			First Named Inventor	Chari
			Group Art Unit	1642
			Examiner Name	RAWLINGS
			Attorney Docket Number	104322.198
Sheet	3	of	3	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SR	M	Panda et al, Proc. Natl. Acad. Sci. USA, 95:9313-9318 (August 1998).	✓
SR	N	Pitot et al, Clinical Cancer Research, 5:525-531 (March 1999).	✓
SR	O	Pettit et al, J. Am. Chem. Soc., 111:5463-5465 (1989).	✓
SR	P	Roguska et al, Protein Engineering, 9(10):895-904 (1996).	✓
SR	Q	Roguska et al, Proc. Natl. Acad. Sci. USA, 91:969-973 (1994).	✓
SR	R	Rygaard et al, Br. J. Cancer, 65:573-577 (1992).	✓
SR	S	Schrappe et al, Cancer Research, 52:3838-3844 (1992).	✓
SR	T	Smith et al, Cancer Research, 54:3779-3784 (1994).	✓
SR	U	Villalona-Calero, Journal of Clinical Oncology, 16(8):2770-2779 (August 1998).	✓
SR	V	Doria et al, Cancer 62:1939-1945 (1988).	✓

Examiner Signature		Date Considered	5/5/02
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

MAY 16 2001

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/671,995
Filing Date	September 29, 2000
First Named Inventor	Chari
Group Art Unit	1642
Examiner Name	M. Trans RAWLING'S
Attorney Docket Number	104322.198

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SR	W	Liu et al, Proc. Natl. Acad. Sci. USA, 93:8618-8623 (August 1996).	
SR	X	Embleton et al, Br. J. Cancer, 47:043-049 (1993).	
SR	Y	Mendelsohn et al, Clin. Cancer Res., 3:2703-2707 (December 1997).	
SR	Z	Ghaemmaghami et al, Chest, 113(Supp. 1):86s-91s (January 1998).	
SR	AA	Christian et al, Gynecologic Oncology, 55:s143-s150 (1994).	

Examiner
Signature

[Signature]

Date
Considered

5/5/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.